Belgium Anti Aging Therapeutics Market Report 2022 to 2030

Belgium Anti Aging Therapeutics Market Analysis

$ 3999

Belgium anti-aging therapeutics market is expected to witness growth from $1 Mn in 2022 to $5 Mn in 2030 with a CAGR of 16.53% for the forecasted year 2022-2030 due to the rising geriatric population and the emergence of novel and more advanced therapeutic options for anti-aging in Belgium. The Belgium anti-aging therapeutics market is segmented by product, treatment, target group, type of aging, type of molecules, mechanism of action, ingredient, and by distribution channel. Bioxodes, Biotalys, and Elysium Health are some of the leading companies in Belgium anti-aging therapeutics market.

ID: IN10BEPH030 CATEGORY: Pharmaceuticals GEOGRAPHY: Belgium AUTHOR: Parul Choudhary

Buy Now

Belgium Anti-Aging Therapeutics Market Executive Summary

The Belgium anti-aging therapeutics market size is at around $1 Mn in 2022 and is projected to reach $5 Mn in 2030, exhibiting a CAGR of 16.53% during the forecast period. According to figures released on Monday by Eurostat, the statistics arm of the European Union, Belgium had the largest budget deficit among Eurozone nations during the third quarter of 2022, coming in at 5.1% of GDP. 3.3% of GDP was the average for the eurozone. Belgium's thriving biotech sector is at the vanguard of advancements in the life sciences, pharmaceuticals, medtech, healthcare, and other fields. According to the federal government, Belgium is home to 7% of Europe's bioscience firms. They represent 16% of the continent's total revenue and nearly 10% of its R&D spending. According to the Belgian Federation for Life Sciences and Biotechnology, sector-specific shipments increased by a factor of two over the course of the previous ten years alone, surpassing $89 Bn in 2021. Spending on R&D rose by 166% during that time, and employment in the sector expanded by 41%.

Verbruggen and co-workers from Vrije Universiteit Brussel in Belgium discovered that the deletion of a particular amino acid transporter called xCT increased lifespan in mice by 13%, decreased inflammation, and enhanced memory. Their findings were published in the journal Molecular Psychiatry. According to these results, inhibiting xCT may help humans age healthily and avoid cognitive decline. In mice, genetic deletion of xCT upsets this equilibrium while also lowering inflammation. Because it worsens with age and is linked to conditions like dementia and cognitive loss, inflammation is a sign of aging. It might be simpler to use a medication that inhibits xCT because deleting genes in humans is challenging. Sulfasalazine is one such medication that has received FDA approval and is currently being used to treat inflammatory illnesses rheumatoid arthritis and inflammatory bowel disease. (IBD). Future treatments for brain aging and longevity promotion may make use of medications like Sulfasalazine, which inhibits the xCT amino acid transporter.

Belgium Anti Aging Therapeutics Market

Market Dynamics

Market Growth Drivers Analysis

A sizable proportion of the populace in Belgium is over 65, which indicates an aging society. People get more prone to age-related illnesses and ailments as they get older, including creases, age spots, and other aging symptoms. As a result of this, there is a demand for anti-aging treatments that can make people feel and appear younger. The Belgium anti-aging therapeutics market is expanding as a result of the emergence of new technologies and treatments. For instance, stem cell treatment and gene therapy are cutting-edge techniques that hold great promise for aging populations. The advancement of new anti-aging therapeutics has been facilitated by the Belgian government's support for research and development in the healthcare field. The government also funds clinical trials and other projects in research that might be helpful to the aging population.

Market Restraints

New anti-aging therapeutics must go through a rigorous regulatory procedure before being approved, and navigating these requirements can be challenging. This may slow innovation and make it more challenging for businesses to launch new goods. While anti-aging therapeutics can aid in reducing the symptoms of aging, numerous cosmetic procedures can also produce equivalent effects. These treatments, like Botox injections and facelifts, are frequently more successful right away and may appeal to customers more. In Belgium, medically necessary treatments are usually the only ones that health insurance will pay for; therefore, anti-aging therapies may not be covered. As a result, many people, especially those with lower incomes, may find it more difficult to obtain these treatments.

Competitive Landscape

Key Players

AgomAb Therapeutics (BEL) - The development of molecular treatments by AgomAb aims to regenerate injured tissues. Their distinct agonistic monoclonal antibody molecules (referred to as "agomAbs") trigger cellular and molecular repair processes that may allow patients with fibrotic, inflammatory, autoimmune, and degenerative diseases to regain organ function.
Atbtherapeutics (BEL)
Biocartis (BEL)
Bioxodes (BEL)
Biotalys (BEL)
Elysium Health
Genome Protection
GenSight Biologics
Intervene Immune
Khondrian
Longeveron
LyGenesis
Mesoblast

Healthcare Policies and Regulatory Landscape

The Federal Agency for Medicines and Health Products (FAMHP) is the regulatory authority in Belgium in charge of approving and regulating anti-aging medications. All medications sold in Belgium must meet FAMHP's strict standards for quality, safety, and efficacy. Clinical trials for anti-aging medications, which are performed in Belgium, must be approved and regulated by FAMHP. The organization makes certain that all clinical trials are carried out in accordance with moral and safety guidelines and that the data produced is correct and trustworthy. The European Medicines Agency (EMA), in addition to FAMHP, is involved in the control of anti-aging medications in Belgium. In the European Union, drug clearance is handled centrally by the EMA, including for anti-aging medications. The organization evaluates the quality, safety, and effectiveness of medications and makes suggestions for their approval.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anti-Aging Therapeutics Market Segmentation

By Product (Revenue, USD Billion):

Anti-Wrinkle
Hair Color
Ultraviolet (UV) Absorption
Anti-Stretch Mark
Others

By Treatment (Revenue, USD Billion):

Hair Restoration
Anti-Pigmentation
Adult Acne Therapy
Breast Augmentation
Liposuction
Chemical Peel
Others

By Target Group (Revenue, USD Billion):

Male
Female

By Type of Aging (Revenue, USD Billion):

Cellular Aging
Immune Aging
Metabolic Aging
Others

By Type of Molecules (Revenue, USD Billion):

Biologics
Small Molecules

By Mechanism of Action (Revenue, USD Billion):

Senolytic
Cell Regeneration
mTOR inhibitor/Modulator
AMP-kinase/AMP Activator
Mitochondria Inhibitor/Modulator
Others

By Ingredient (Revenue, USD Billion):

Retinoid
Hyaluronic Acid
Alpha Hydroxy Acid
Others

By Distribution Channel (Revenue, USD Billion):

Pharmacies
Stores
Online Stores

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.